Study objective: To determine the relationship between airway hyperreactivity (AHR) and endobronchial involvement in patients with sarcoidosis. Design: Prospective series of consecutive patients. Setting: Pulmonary clinic of a military, tertiary-care teaching hospital. Patients: Patients with newly diagnosed sarcoidosis. Interventions: All patients undergoing bronchoscopy for the diagnosis of sarcoidosis underwent an evaluation that included history, physical examination, chest radiography, and spirometry. Bronchoprovocation testing was done using methacholine. During bronchoscopy, six endobronchial biopsy (EBB) specimens were obtained. In patients with abnormal-appearing airways, four specimens were obtained from abnormal areas and two specimens were obtained from the main carina. In patients with normal-appearing airways, four specimens were obtained from a secondary carina and two specimens were obtained from the main carina. A biopsy specimen was considered positive if it demonstrated nonnecrotizing granulomas with special stains that were negative for fungal and mycobacterial organisms. Only patients with histologic confirmation of sarcoidosis were included in the data analysis. 
S
arcoidosis is a multisystem disease of unknown etiology that predominantly affects the lungs and intrathoracic lymph nodes. Nonnecrotizing granulomas are found in affected organs, and T-cell function plays a role in the development of sarcoidosis. Earlier studies 1 reported a heightened T-cell type 1 response at sites of involvement. Conversely, B-cell hyperactivity and circulating immune complexes have also been reported 1,2 in patients with sarcoidosis. In some patients, the disease is found when incidental findings are observed on a chest radiograph (CXR); in others, the disease produces significant clinical symptoms. Occasionally, sarcoidosis results in lung fibrosis and scarring.
Airway hyperreactivity (AHR) has been report- [3] [4] [5] [6] to occur in 5 to 83% of patients with sarcoidosis. For example, Marcias and coworkers 3 observed AHR in 20.6% of patients with sarcoidosis, while Bechtel et al 4 noted AHR in 50.0% of patients with sarcoidosis. The wide reported range in the incidence of AHR in patients with sarcoidosis likely reflects differences in study design and patient selection. Earlier studies on this topic have included patients lacking a formal histologic diagnosis, employed differing definitions of AHR, and were completed prior to the development of formal guidelines 7 for the conduct and interpretation of bronchoprovocation testing. Identifying AHR in patients with sarcoidosis may have important clinical implications. Some individuals with sarcoidosis, despite normal spirometric findings and normal lung parenchyma shown on CXR, complain of dyspnea, cough, and wheeze. 1, 2, 8 The presence of AHR may explain these symptoms. Similarly, AHR may also indicate that patients have symptoms that might respond to treatment with inhaled rather than oral corticosteroids. Chronic airflow obstruction, a possible sequelae of untreated AHR, has been shown to portend a worse prognosis in patients with sarcoidosis. 9 Fixed airflow obstruction in sarcoidosis is associated not only with parenchymal lung involvement, but it also has been shown 9 to nearly double the risk for mortality.
Factors associated with AHR in patients with sarcoidosis remain unknown. Some have suggested that AHR is associated with worse pulmonary function as measured by spirometry, while others have found no link between the results of pulmonary function tests (PFTs) and AHR. [3] [4] [5] [6] Moreover, the mechanism of AHR in patients with sarcoidosis has not been elucidated. Endobronchial granulomas, which are noted in approximately half of the patients with sarcoidosis, may lead to AHR by either elaborating mediators that promote inflammation or by altering cholinergic receptors in the airways. No studies have correlated the finding from endobronchial biopsy (EBB) with the results of bronchoprovocation testing in patients with sarcoidosis. We hypothesized that endobronchial involvement would be a risk factor for AHR. To test our hypothesis, we conducted a prospective study in consecutive patients with newly diagnosed sarcoidosis to explore the relationship between the results of EBB and bronchoprovocation challenge.
Materials and Methods

Subjects
All patients referred to our pulmonary clinic between July 1997 and December 2000 with suspected sarcoidosis were eligible to participate in this study. This protocol represents a follow-up study to an earlier project 10 to determine the yield of EBB for suspected sarcoidosis. Subjects from the original investigation 10 were allowed to participate in this study. The diagnosis of sarcoidosis was based on the histologic demonstration of nonnecrotizing granulomas with special stains that failed to reveal either fungal or mycobacterial organisms. Patients with only a clinical diagnosis of sarcoidosis were not eligible for this study. Other exclusion criteria included previous treatment with corticosteroids in any form over the preceding 12 months, a prior diagnosis of asthma, a history of atopy, and age Ͻ 18 years. The study was approved by the Walter Reed Army Medical Center Human Use Committee, and each subject provided informed, written consent.
Evaluation
All subjects underwent a standard evaluation that included a history and physical examination, a CXR, and PFTs with measurement of the single-breath diffusion capacity of the lung for carbon monoxide (Dlco). Radiographic stages were defined as follows: stage 0, normal CXR finding; stage I, bilateral hilar lymphadenopathy alone; stage II, bilateral hilar lymphadenopathy with interstitial infiltrates; and stage III, interstitial infiltrates alone. The PFTs and Dlco were interpreted in accordance with the guidelines of the American Thoracic Society (ATS). 11 Normal values were derived from Crapo et al, 12 and corrections for race were made. Dlco was further corrected for hemoglobin. Values for PFTs and Dlco were considered abnormal if they fell outside the 95% confidence interval (CI) for the predicted values. The erythrocyte sedimentation rate (ESR) and the angiotensin-converting enzyme (ACE) level were measured. The ACE level was determined via an enzymatic assay (Quest Diagnostics; Baltimore, MD). The normal range for this at our institution varies from 8.0 to 52.0 IU/L. The presence of pulmonary symptoms (dyspnea, cough, and wheezing) was determined from a standard questionnaire completed by all subjects on enrollment.
Bronchoprovocation Testing
For bronchoprovocation testing, we used methacholine. The five-breath dosimeter method originally described by Chai et al 13 was used, with patients inhaling increasing doses of methacholine: 0.025, 0.25, 2.5, 10.0, and 25.0 mg/mL. AHR was considered present at the provocative dose of methacholine causing a 20% fall in FEV 1 (PD 20 ). After the initiation of this study, the ATS published new guidelines 7 for methacholine challenge testing that recommended a different dosing regimen and proposed an alternative interpretive strategy based on the provocative concentration of methacholine causing a 20% fall in FEV 1 . These guidelines became available after our study began enrollment. Therefore, for the sake of consistency and reproducibility, we relied on the dosing schedule of Chai et al. 13 The severity of AHR was graded as follows: PD 20 Ͻ 20 breath units (BUs), severe; 21 to 50 BUs, moderate; 51 to 188.88 BUs, mild. However, after our initial data analysis of the relationship between the yield of EBB and AHR based on the PD 20 , we reassessed the data employing the currently proposed definition of a positive methacholine challenge result. Under the most recent rubric, 7 a methacholine challenge test result is considered positive if the provocative concentration of methacholine causing a 20% fall in FEV 1 is Յ 16 mg/mL.
Bronchoscopy
Fiberoptic bronchoscopy was performed in standard fashion in all patients, with six EBB specimens obtained. For patients with abnormal-appearing airways, four specimens were obtained from the abnormal-appearing airways and two specimens were obtained from the main carina. In patients with normal-appearing airways, four specimens were obtained from a secondary carina and two specimens were obtained from the main carina. An 18-mm, smooth-edged jaws forceps (Boston Scientific; Watertown, MA) was used. Pathologists reviewing the specimens were blinded not only to the patient's clinical presentation (eg, symptoms, CXR findings) but also to the results of the bronchoprovocation testing. An EBB specimen was considered positive if it revealed nonnecrotizing granulomas with specials stains that failed to show either mycobacterial or fungal organisms.
Statistical Analysis
Patients with AHR were compared to those with negative bronchoprovocation challenge findings with respect to the following: (1) the results of EBB, and (2) the variables noted above. The Student's t test was used for the analysis of continuous variables. The 2 was employed to compare categorical variables except in cases when expected values were small. In these instances, we relied on the Fisher's Exact Test. The distribution of CXR stages was analyzed via the Wilcoxon rank-sum test. All tests were two tailed, and a p Ͻ 0.05 was assumed to represent statistical significance. Ninety-five percent CIs are reported where appropriate. Analyses were done using software (SPSS version 9.0; SPSS; Chicago, IL).
Results
During the study period, 45 consecutive patients referred for suspected sarcoidosis were screened for participation. Three patients were excluded (two patients with a history of asthma, and one patient for recent use of inhaled corticosteroids), leaving 42 individuals in the study cohort. The mean age (Ϯ SD) was 37.3 Ϯ 6.5 years, and 57.1% were men. The majority of patients (61.9%) were African American. A stage I CXR was noted in 28 patients, and stage II and stage III CXRs were seen in 12 patients and 2 patients, respectively. Five patients (11.9%) had extrapulmonary sarcoidosis at the time of presentation (two patients with uveitis, two patients with skin lesions, and one patient with extrapulmonary lymph nodes). No patients reported symptoms lasting Ͼ 3 months prior to bronchoscopy. The diagnosis of sarcoidosis was based on EBB alone in 8 patients and by transbronchial biopsy (TBB) alone in 12 patients. In 16 instances both EBB and TBB findings were positive. In the remaining patients, diagnostic tissue was obtained via mediastinoscopy. All were nonsmokers, and 40 of the 42 patients were neversmokers. The remaining two patients subjects had ceased tobacco use Ͼ 10 years before the evaluation for sarcoidosis.
The methacholine challenge test result was positive in nine patients (21.4%; 95% CI, 10.3 to 36.8%). In four patients, AHR was mild, while it was moderate in three patients. In only two patients was AHR severe. As shown in Table 1 , 24 patients (57.1%) had EBB specimens demonstrating nonnecrotizing granulomas. All nine of the patients (100%) with AHR had positive EBB findings, as compared to 15 of the 33 patients (45.5%) with negative bronchoprovocation challenge results (p ϭ 0.005). The relative risk for AHR associated with the presence of nonnecrotizing granulomas on EBB was estimated to be 11.9 (95% CI, 1.5 to 103.9). There was no association between AHR and airway appearance. The incidence of abnormal-appearing airways (defined as either erythema or mucosal thickening) was similar among those with AHR and those without AHR.
There was no difference in the demographic compositions of the cohorts with or without AHR. For spirometric measurements, there was a trend toward both a lower FEV 1 and FVC in the subjects demonstrating AHR, but these differences did not reach statistical significance (Table 2 ). For example, the FEV 1 was 78.8 Ϯ 15.0% of predicted in patients with AHR as compared to 88.7 Ϯ 15.4% of predicted for patients without AHR (p ϭ 0.080). Similarly, the FVC was 82.8 Ϯ 13.1% of predicted in subjects with positive bronchoprovocation test results as compared to 91.1 Ϯ 12.9% of predicted in patients with negative methacholine challenge results (p ϭ 0.098). There was no difference between the groups for the FEV 1 /FVC ratio. Neither the incidence of airflow obstruction (as defined by an abnormal FEV 1 /FVC ratio) nor the presence of a restrictive pattern correlated with the results of bronchoprovocation challenges. Finally, the Dlco and the Dlco/alveolar volume were slightly higher for patients with AHR. As Table 2 shows, these differences were not statistically significant. The CXR stage also did not differ with respect to AHR. Neither the presence nor type of patient-reported symptoms were associated with AHR. The incidence of dyspnea, cough, and wheezing failed to segregate patients with AHR from those without AHR (Table  2) . When symptoms were analyzed as either present or absent, there was no relationship with the outcome of bronchoprovocation testing. In other words, the appearance of symptoms commonly thought to be reflective of airway disease did not aid in determining the potential findings on methacholine challenge testing. Of the often-employed serum markers in the management of sarcoidosis, only the ACE level correlated with the incidence of AHR ( Table  2 ). The ACE level was significantly higher in those individuals showing AHR (79.3 Ϯ 53.9 IU/L vs 37.5 Ϯ 26.7 IU/L, p ϭ 0.050). However, the ESR did not differ based on the results of methacholine challenge. Only one of the patients with extrapulmonary sarcoidosis had AHR. This difference, though, was not statistically significant.
When we reanalyzed our findings employing the new, stricter definition of AHR proposed in the most recent ATS guidelines, two patients who had been categorized as having AHR no longer met the criteria for AHR. The relationship between EBB and AHR remained statistically significant (p ϭ 0.014). The difference in ACE levels observed when using the PD 20 criteria for AHR was no longer present. Additionally, there continued to be no relationship between any of the other variables we examined and the results of bronchoprovocation testing.
Discussion
This prospective study of consecutive patients with newly diagnosed pulmonary sarcoidosis demonstrates that AHR occurs in approximately 20% of such individuals. More importantly, the appearance of AHR is strongly linked to the results of EBB. The presence of endobronchial involvement may be an important step pathophysiologically in the development of AHR in patients with sarcoidosis. Other clinical factors do not seem to predict the presence of AHR.
Previous studies [3] [4] [5] [6] have examined either the clinical implications of endobronchial granulomas or risk factors for AHR in patients with sarcoidosis. None of these efforts, however, has investigated a possible relationship between the two. In an early study of AHR in patients with sarcoidosis, Bechtel et al 4 noted positive methacholine challenge results in 50.0% of patients. They further observed that subjects with AHR had worse spirometry results as measured by FVC, FEV 1 /FVC ratio, and Dlco. The disparity of these findings as compared to our observations regarding both the incidence of and possible clinical markers for AHR likely results from the fact that Bechtel et al 4 studied a convenience sample rather than an unselected sample of consecutive patients, and included patients currently being treated with corticosteroids. 4 Presas and colleagues 14 examined the incidence of AHR in patients with stage I sarcoidosis using methacholine. In their sample of 12 subjects, 6 subjects demonstrated AHR. However, they failed to find a relationship between baseline spirometry and the results of bronchoprovocation testing. Confirming the lack of a correlation between prechallenge PFTs and AHR, Marcias et al 3 reported AHR in 26.6% of individuals with sarcoidosis but found responders and nonresponders had similar baseline FEV 1 , FVC, and FEV 1 /FVC ratios. For example, the mean FEV 1 in subjects with AHR was 91% of predicted compared to 103% of predicted in those without AHR. Although we noted a statistical trend toward worse PFT results in association with AHR, our findings build on these earlier studies. By validating in a larger, untreated sample of patients with sarcoidosis that spirometry is unlikely to be of value in determining if AHR is present, our results suggest that formal bronchoprovocation testing to evaluate persistent symptoms may be indicated irrespective of normal screening spirometry results.
We also noted a higher serum ACE level in patients with AHR. Although the initial relationship between ACE and sarcoidosis was described in 1975, 15 most prior investigations into AHR and sarcoidosis have not reported data regarding either serum markers of disease activity or inflammation. However, Niimi et al 16 examined the relationship between ACE gene polymorphisms and AHR in patients with sarcoidosis; in a study of 21 patients, they found differences in AHR based on the ACE genotype. They further observed a weak correlation between the serum ACE level and AHR as measured by changes in respiratory resistance. Since ACE inhibits the breakdown of bradykinin, a potent bronchoconstrictor and inflammatory mediator, the link between serum ACE levels and AHR suggests that ACE may directly mediate AHR in patients with sarcoidosis. Nonetheless, the role for ACE is likely limited. Specifically, when a more stringent definition of AHR was employed, the relationship we noted between AHR and ACE was no longer present.
Patients with endobronchial involvement from sarcoidosis are at significantly increased risk for AHR. Endobronchial granulomas may play a role in the development of AHR in one of several ways. First, endobronchial granulomas may lead to airway narrowing. Some researchers have postulated that a smaller airway lumen directly increases the risk for AHR. 17 Second, the presence of endobronchial granulomas may disrupt, uncover, or stimulate cholinergic receptors, which, in turn, may enhance AHR. Supporting this possibility, Laitinen et al 17 reported that electron microscopy of EBB specimens in three subjects with sarcoidosis and AHR revealed damaged superficial afferent nerve endings. Electron microscopy further demonstrated extensive epithelial damage and injury to the basement membrane. Finally, the granulomas themselves may elaborate mediators that directly promote AHR. 18 Irrespective of the possible mechanisms for the association between endobronchial involvement and AHR in patients with sarcoidosis, other factors must also be involved. More specifically, the majority of patients with positive EBB results failed to demonstrate AHR. Similarly, no patients with a negative EBB result had AHR. This suggests that endobronchial involvement likely is a necessary precondition for the development of AHR. Conversely, the isolated presence of endobronchial granulomas is insufficient to explain AHR pathophysiologically in this disease.
Our study has several limitations. The first limitation is that the majority of the patients in this study were men, while sarcoidosis is seen more frequently in women. 1, 2 This may limit the generalizability of our findings. The study population, though, was similar to the typical sarcoidosis population in the United States, in that it predominantly consisted of young, African-American patients with stage I CXR findings. Second, because of the sample size, the study may have been underpowered to identify variables that would segregate patients with AHR from those with negative methacholine challenge results. For example, the trend toward a difference in spirometry findings between patients with and without AHR might have reached statistical significance with a larger sample. This fact also explains why the p value increased when we reanalyzed our results using the stricter definition of AHR. With a lower incidence of AHR, the relationship between AHR and EBB was not as strong. Nonetheless, our study was larger than earlier investigations [3] [4] [5] [6] of AHR in sarcoidosis and was less subject to bias in that we prospectively enrolled consecutive patients. Third, EBB may be prone to sampling error. In other words, patients who were categorized as lacking endobronchial involvement may have had endobronchial granulomas identified if more samples were taken from other parts of the airway. Finally, we examined patients at only one point in time. Our study does not preclude the possibility that AHR may develop later in the course of sarcoidosis.
In conclusion, AHR may be seen in patients with sarcoidosis. The presence of endobronchial granulomas significantly increases the risk for AHR. Additionally, endobronchial granulomas likely play a role in the development of AHR in patients with sarcoidosis. Other clinical variables are not clearly associated with AHR in patients with sarcoidosis. Further studies are warranted to elucidate the clinical significance of endobronchial involvement in sarcoidosis and to examine if AHR in patients with sarcoidosis changes over time or with treatment.
